{
    "clinical_study": {
        "@rank": "100983", 
        "arm_group": [
            {
                "arm_group_label": "Mild renal impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Moderate renal impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Severe renal impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "End stage renal disease arm 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "End stage renal disease arm 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To study the blood concentrations of POL7080 in subjects with impaired renal function."
        }, 
        "brief_title": "Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Subjects who signed informed consent.\n\n          -  2. Male subjects \u226518 and \u226479 years of age; female subjects \u226518 and     \u226479 years of\n             age of non-childbearing potential\n\n          -  3. Weight within a BMI range of 19.0-35.0 kg/m2.\n\n          -  4. CLCr according to Cockcroft Gault equation of:\n\n               -  50-80 mL/min (mild renal impairment)\n\n               -  30- <50 mL/min (moderate renal impairment)\n\n               -  <30 mL/min (severe renal impairment)\n\n               -  subjects receiving dialysis for \u22653 months before dosing (ESRD)\n\n        Exclusion Criteria:\n\n          -  1. Unwilling or unable to give informed consent.\n\n          -  2. As a result of the medical screening process, the study physician considers the\n             subject unfit for the study.\n\n          -  3. Demonstrating excess in xanthine consumption (more than 5 cups of coffee or\n             equivalent per day).\n\n          -  4. Subjects who smoke more than 10 cigarettes a day.\n\n          -  5. Subjects who consume more than 28 units (males) or more than 21 units (females) of\n             alcohol per week.\n\n          -  6. Any history of hypersensitivity to the IMP.\n\n          -  7. For subjects with renal impairment: No clinically significant change in disease\n             status within at least 1 month prior to study entry, as determined by the\n             investigator.\n\n          -  8. The subject had donated a unit of blood (450 mL) within the 3 months before\n             dosing, or intends to donate in the month after the last scheduled visit.\n\n          -  9. Participation in another clinical study with an investigational drug or device\n             within the last month.\n\n          -  10. Subjects with clinically significant telemetric ECG abnormalities on Day -1\n\n          -  11. Significant allergies requiring intranasal or systemic corticosteroids during any\n             time of the year or history of any anaphylactic reaction.\n\n          -  12. Positive test for human immunodeficiency virus (HIV) antibodies.\n\n          -  13. Acute Hepatitis B or C infection.\n\n          -  14. The subject has tested positive for drugs of abuse at screening.\n\n          -  15. Subjects who have received any prescribed systemic or topical medication within 4\n             weeks prior to dosing (excluded are those drugs the renally impaired subject is\n             currently taking for treatment of the renal or concomitant disease).\n\n          -  16. Immunocompromised patients (patients after solid organ or bone marrow transplant;\n             patients receiving immunosuppressive treatment).\n\n          -  17. Subjects with known or suspected Pseudomonas infection or colonization (e.g.\n             patients with cystic fibrosis)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110459", 
            "org_study_id": "POL7080-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "Mild renal impairment", 
                "Moderate renal impairment", 
                "Severe renal impairment", 
                "End stage renal disease arm 1", 
                "End stage renal disease arm 2"
            ], 
            "description": "Intravenous infusion", 
            "intervention_name": "POL7080", 
            "intervention_type": "Drug", 
            "other_name": "POL7080"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "POL7080", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kiel", 
                    "country": "Germany", 
                    "zip": "24105"
                }, 
                "name": "CRS Clinical Research Services Kiel GmbH"
            }, 
            "investigator": {
                "last_name": "Atef Halabi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment", 
        "overall_contact": {
            "email": "Klaus.Dembowsky@polyphor.com", 
            "last_name": "Klaus Dembowsky, MD", 
            "phone": "+44 61 567 16 00"
        }, 
        "overall_contact_backup": {
            "email": "Manickam.Rangaraju@polyphor.com", 
            "last_name": "Manickam Rangaraju, MD", 
            "phone": "+44 61 567 16 00"
        }, 
        "overall_official": {
            "affiliation": "CRS Clinical Research Services Kiel GmbH", 
            "last_name": "Atef Halabi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medicinal Devices (BfArM)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To measure the plasma concentrations of POL7080", 
            "safety_issue": "No", 
            "time_frame": "at baseline, 0.5, 1,1.5 and 3 hours after start of infusion, at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 and 72 hours after end of infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110459"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of adverse events reported by the patients or observed by the investigator will be recorded. Onset, end date, severity, causal relationship, outcome and measures taken will be summarized. Discontinuations and serious adverse events will be listed and narrative summaries will be provided.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Daily assessment up to 7 days from informed consent"
            }, 
            {
                "description": "The number and severity of blood chemistry and hematology findings will be summarized descriptively and compared to baseline.", 
                "measure": "Laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day -1, Day 2, Day 3, and Day 7"
            }
        ], 
        "source": "Polyphor Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polyphor Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}